[Treatment of carcinoma in situ of the urinary bladder with BCG].
In a prospective study 55 patients with primary or secondary carcinoma in situ of the bladder were treated with BCG. With an overall response rate of 85%, results reported by other authors can be confirmed. In relationship with the effectiveness of the treatment, the side-effects can be considered as acceptable. Therapy failure suggests extravesical or invasive carcinoma.
Schnyder von Wartensee
M
M
Ackermann
D
D
Studer
U E
UE
Zingg
E J
EJ
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine
Die Behandlung des Carcinoma in situ der Harnblase mit BCG.